The concomitant targeting of VEGF and estrogen pathways may provide enhanced benefit in patients with hormone‐receptor positive BC, with preclinical and clinical data supporting the hypothesis of a synergistic action (Bottini et al., 2006; Qu et al., 2008; Suriano et al., 2008; Banerjee et al., 2010; Forero‐Torres et al., 2010; Traina et al., 2010; Yardley et al., 2011). The gene discussed is VEGFA; the disease is breast cancer.